People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic ...

GLP-1RAs were associated with a reduced risk for neurodegenerative and cerebrovascular diseases in type 2 diabetes and obesity.

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.

Today, we're diving into a hot topic in the world of health and wellness: semaglutide. You might have heard about this medication in the context of weight loss. While it's a promising tool, it's ...

Weight Loss RX Reviews today published their groundbreaking "2025 American Compounded Semaglutide Consumer Insight Report" – ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...